Handelsavisen
prelaunch
Companies Health Care 044480.KQ
04
044480.KQ KOE Pharmaceuticals

044480.Kq

$954,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
LatestTrump Announces 5,000 Troop Deployment to Poland, NATO Pledges Billions for Defense
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
77,0B KRW
P/E
EV / Rev
Div yield
Op margin
-7,6 %
ROE
-29,1 %
Net margin
-28,2 %
Debt / equity
0,62
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
42
composite score
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-29,1 %
return on equity
Quality
56
quality score (0-100)

News & coverage

3
  • NEWSTrump Announces 5,000 Troop Deployment to Poland, NATO Pledges Billions for Defense2026-05-22
  • MARKETSCoreWeave Q1 Revenue Surpasses Estimates, Shares Drop in After-Hours Trading2026-05-07
  • MARKETSTrump Administration Begins Paying Tariff Refunds, Spurring Market Reactions2026-05-06
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,1 %+0,7 %+2,5 %
    Energy+1,1 %+5,5 %+1,5 %
    Health Care · THIS SECTOR+0,6 %−0,4 %+1,0 %
    Consumer Discretionary+0,4 %+5,7 %+0,8 %
    Information Technology−0,3 %+4,8 %+0,1 %
    Financials−0,5 %−3,5 %−0,1 %
    Real Estate−0,7 %+10,8 %−0,3 %
    Consumer Staples−0,8 %+4,5 %−0,4 %
    Utilities−1,5 %−21,2 %−1,1 %
    Industrials−1,7 %−2,4 %−1,3 %
    Communication Services

    Developing storylines

    No tracked sagas currently linked to 044480.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-06-25 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-06-25 · SE
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
    • Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
    • Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Composite score42 / 100
    Composite score 0-100 · Data quality 0,56
    Data quality0,56 / 1.00

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.9, suggesting limited short-term liquidity cushion. The company's price-to-book ratio is 4.61, and its price-to-tangible-book ratio is also 4.61, reflecting a premium valuation relative to its book value. However, the company's negative net income of -7,133,786,860 KRW and negative operating income of -1,931,629,150 KRW indicate a challenging earnings environment.

    Profitability metrics show a return on equity of -0.291 and a return on assets of -0.1465, both significantly below zero, which is a clear sign of unprofitability. The company's gross profit of 5,114,262,620 KRW is modest compared to its revenue of 25,309,657,430 KRW, indicating a low gross margin. The operating cash flow of 721,547,130 KRW is positive but insufficient to cover the negative net income, highlighting operational inefficiencies.

    The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess geographic or segment concentration. However, the lack of detailed segment reporting suggests a potential concentration risk, as the company's performance is not diversified across multiple markets or product categories.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative net income and operating income suggest a lack of growth momentum. The company's free cash flow is negative at -6,416,300,730 KRW, indicating that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs.

    The company's risk profile includes a medium liquidity risk, as indicated by the current ratio of 0.9. The risk assessment also notes that net cash is negative after subtracting total debt, which could pose a challenge in meeting short-term obligations. The dilution risk is assessed as low, and there are no immediate signs of dilution pressure from recent issuance or shelf registration.

    Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The most recent analyst estimate for EPS is -1,491.74 KRW, reflecting a continued negative earnings trend. The absence of detailed recent events or transcripts limits the ability to assess the company's near-term strategic direction.

    Key takeaways
    • The company is currently unprofitable, with a negative net income and operating income.
    • The company's liquidity position is weak, with a current ratio of 0.9 and a negative net cash position after debt.
    • The company's valuation is premium, as indicated by a price-to-book ratio of 4.61, but this is not supported by positive earnings.
    • The company's growth trajectory is unclear, with no specific revenue growth projections provided.
    • The company's risk profile includes medium liquidity risk and low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $954,00
    Market cap
    $112.93B
    Enterprise value
    $114.78B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    159.1x
    P / B
    4.6x
    P / Tangible book
    4.6x
    Tangible book
    $24.52B
    Net cash
    -$1.85B
    Current ratio
    0.9
    Debt / equity
    0.6
    ROA
    -14.6%
    ROE
    -29.1%
    Cash conversion
    -10.0%
    CapEx / revenue
    -1.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Forward curve

    — missing data

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    — missing data

    Benchmarks vs cohort

    Op Margin-7,6 %Bottom quartile
    Net Margin-28,2 %Bottom quartile
    ROE-29,1 %Bottom quartile
    Capex / Rev-1,5 %Above P75
    D/E0,62Bottom quartile
    Cash Conv-0,10Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 044480.KQ Market data — financials · 2026-05-26
    • Billions Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Seong Hun KimPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    044480.KQCanonical
    KOE · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-06-25 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage